MarketBeat
15 Aug 2026, 06:02 UTC · 2h ago
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
15 Aug 2026, 06:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Pulmonx plans to commercialize its AeriSeal therapy outside the U.S. in the second half of next year, potentially expanding the eligible patient population for its valve treatment from 80% to 95%. — Expanding the addressable market via a new product that enables more patients to receive the core valve treatment is a significant long-term growth catalyst.
+0.60The company raised its gross-margin outlook to approximately 76% and lowered its operating-expense outlook to $109 million–$111 million. — Improved margins and reduced spending indicate better operational efficiency and a clearer path toward profitability.
+0.40Pulmonx has filled sales leadership openings and most open territories following high turnover in 2025 to stabilize its U.S. commercial execution. — Stabilizing the sales force is a prerequisite for returning to growth, though it is an operational recovery rather than a new growth driver.
+0.30Continue reading
6 related stories
Search tags
The company expects to restart commercial activity in China with the first shipment to its distributor occurring no later than early next year. — While returning to a major market is positive, the previous revenue baseline was relatively small ($2M-$2.5M) compared to total guidance.
+0.20Pulmonx reiterated its full-year revenue guidance of $90 million to $92 million. — Reiterating existing guidance is a neutral event as it matches current market expectations.
+0.00Which stocks this story touches
The company is rebuilding its sales organization, raising its gross-margin outlook, and preparing for new product commercialization.
Its Ion platform is credited with elevating the standing of pulmonology within hospitals, creating a more favorable environment for the sector.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
15h ago
